Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma

Carfilzomib is a second-generation proteasome inhibitor with well-documented clinical activity as a single agent in patients with relapsed/refractory multiple myeloma. Carfilzomib can partially overcome resistance in bortezomib-refractory patients and has significant efficacy in bortezomib-naïve pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Fostier, Karel, De Becker, Ann, Schots, Rik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463411/
https://www.ncbi.nlm.nih.gov/pubmed/23055749
http://dx.doi.org/10.2147/OTT.S28911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463411/
https://www.ncbi.nlm.nih.gov/pubmed/23055749
http://dx.doi.org/10.2147/OTT.S28911

Ejemplares similares